Novo Nordisk
NVO
1,307 hedge funds and large institutions have $27.6B invested in Novo Nordisk in 2023 Q3 according to their latest regulatory filings, with 192 funds opening new positions, 497 increasing their positions, 403 reducing their positions, and 65 closing their positions.
195% more first-time investments, than exits
New positions opened: 192 | Existing positions closed: 65
32% more funds holding in top 10
Funds holding in top 10: 47 → 62 (+15)
23% more repeat investments, than reductions
Existing positions increased: 497 | Existing positions reduced: 403
19% more capital invested
Capital invested by funds: $23.2B → $27.6B (+$4.38B)
9% more funds holding
Funds holding: 1,197 → 1,307 (+110)
7.97% less ownership
Funds ownership: 16.71% → 8.74% (-8%)
38% less call options, than puts
Call options by funds: $666M | Put options by funds: $1.07B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Polen Capital Management
Boca Raton,
Florida
|
+$696M |
| 2 |
SFM
Soros Fund Management
New York
|
+$134M |
| 3 |
Fayez Sarofim & Co
Houston,
Texas
|
+$120M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$109M |
| 5 |
Envestnet Asset Management
Chicago,
Illinois
|
+$88.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$221M |
| 2 |
Capital International Investors
Los Angeles,
California
|
-$99.8M |
| 3 |
Millennium Management
New York
|
-$75.4M |
| 4 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$63.4M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$59.1M |
NVO Hedge Fund Activity: Q3 2023 in Review
1,307 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Novo Nordisk (NVO) for Q3 2023, worth a combined $27.6B — up 19% from $23.2B a quarter earlier.
Buyers outnumbered sellers: 192 funds opened new NVO positions and 65 closed out — a net gain of 127 holders — while 497 added to existing stakes and 403 trimmed.
The largest buyer was Polen Capital Management, opening a new position worth an estimated $696M. The largest seller was Renaissance Technologies, cutting an estimated $221M.
- 1,307 institutional investors held Novo Nordisk (NVO) as of Q3 2023, up from 1,197 in Q2 2023.
- Funds reported $27.6B of Novo Nordisk stock for Q3 2023, up 19% quarter-over-quarter.
- 192 funds opened new Novo Nordisk positions in Q3 2023 and 65 closed out, a net change of +127 holders.
- The largest Novo Nordisk buyer in Q3 2023 was Polen Capital Management, an estimated $696M added.
- The largest Novo Nordisk seller in Q3 2023 was Renaissance Technologies, an estimated $221M sold.
Based on aggregated 13F filings for Q3 2023.